APO RESEARCH · REPORT
Human Fibrinogen
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Human Fibrinogen is used as a medicine for blood disease. Human Fibrinogen is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Product & engineering
Understand the product.
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Human Fibrinogen is used as a medicine for blood disease. Human Fibrinogen is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Selected research
Market Structure
Global Human Fibrinogen Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Human Fibrinogen is used as a medicine for blood disease. Human Fibrinogen is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Global Human Fibrinogen key players include CSL Behring, LFB Group, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, GREEN CROSS, etc. Global top five manufacturers hold a share about 90%. Asia-Pacific is the largest consumption market, with a share about 60%, followed by Americas and Europe, total have a share over 30 percent. In terms of product, Human Fibrinogen Concentrate is the largest segment, with a share over 99%. And in terms of application, the largest application is Surgical Procedures.
This report provides an overview of the global Human Fibrinogen market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Human Fibrinogen and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human Fibrinogen sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Fibrinogen market size, projected growth trends, production technologies, key applications, and end-use industries.
Human Fibrinogen Segment by Company
CSL Behring
LFB Group
Shanghai RAAS Blood Products
Jiangxi Boya Bio-Pharmaceutical
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
GREEN CROSS
Shanghai XinXing Medical
Octapharma
Human Fibrinogen Segment by Type
Human Fibrinogen Concentrate
Animal Fibrinogen Concentrate
Human Fibrinogen Segment by Application
Congenital Fibrinogen Deficiency
Surgical Procedures
Human Fibrinogen Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Fibrinogen market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Fibrinogen and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Fibrinogen.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Human Fibrinogen market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Fibrinogen manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Human Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Human Fibrinogen Concentrate
- Animal Fibrinogen Concentrate
Applications
- Congenital Fibrinogen Deficiency
- Surgical Procedures
Companies covered
- CSL Behring
- LFB Group
- Shanghai RAAS Blood Products
- Jiangxi Boya Bio-Pharmaceutical
- Hualan Biological Engineering
- Harbin Pacific Biopharmaceutical
- GREEN CROSS
- Shanghai XinXing Medical
- Octapharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Human Fibrinogen Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Human Fibrinogen Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Human Fibrinogen Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Human Fibrinogen Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Human Fibrinogen Market Dynamics
- 2.1 Human Fibrinogen Industry Trends
- 2.2 Human Fibrinogen Industry Drivers
- 2.3 Human Fibrinogen Industry Opportunities and Challenges
- 2.4 Human Fibrinogen Industry Restraints
3 Human Fibrinogen Market by Manufacturers
- 3.1 Global Human Fibrinogen Revenue by Manufacturers (2021-2026)
- 3.2 Global Human Fibrinogen Sales by Manufacturers (2021-2026)
- 3.3 Global Human Fibrinogen Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Human Fibrinogen Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Human Fibrinogen Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Human Fibrinogen Manufacturers, Product Type & Application
- 3.7 Global Human Fibrinogen Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Human Fibrinogen Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Human Fibrinogen Players Market Share by Revenue in 2025
- 3.8.3 2025 Human Fibrinogen Tier 1, Tier 2, and Tier 3
4 Human Fibrinogen Market by Type
- 4.1 Human Fibrinogen Type Introduction
- 4.1.1 Human Fibrinogen Concentrate
- 4.1.2 Animal Fibrinogen Concentrate
- 4.2 Global Human Fibrinogen Sales by Type
- 4.2.1 Global Human Fibrinogen Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Human Fibrinogen Sales by Type (2021-2032)
- 4.2.3 Global Human Fibrinogen Sales Market Share by Type (2021-2032)
- 4.3 Global Human Fibrinogen Revenue by Type
- 4.3.1 Global Human Fibrinogen Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Human Fibrinogen Revenue by Type (2021-2032)
- 4.3.3 Global Human Fibrinogen Revenue Market Share by Type (2021-2032)
5 Human Fibrinogen Market by Application
- 5.1 Human Fibrinogen Application Introduction
- 5.1.1 Congenital Fibrinogen Deficiency
- 5.1.2 Surgical Procedures
- 5.2 Global Human Fibrinogen Sales by Application
- 5.2.1 Global Human Fibrinogen Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Human Fibrinogen Sales by Application (2021-2032)
- 5.2.3 Global Human Fibrinogen Sales Market Share by Application (2021-2032)
- 5.3 Global Human Fibrinogen Revenue by Application
- 5.3.1 Global Human Fibrinogen Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Human Fibrinogen Revenue by Application (2021-2032)
- 5.3.3 Global Human Fibrinogen Revenue Market Share by Application (2021-2032)
6 Global Human Fibrinogen Sales by Region
- 6.1 Global Human Fibrinogen Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Human Fibrinogen Sales by Region (2021-2032)
- 6.2.1 Global Human Fibrinogen Sales by Region (2021-2026)
- 6.2.2 Global Human Fibrinogen Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Human Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Human Fibrinogen Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Human Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Human Fibrinogen Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Human Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Human Fibrinogen Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Human Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Human Fibrinogen Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Human Fibrinogen Revenue by Region
- 7.1 Global Human Fibrinogen Revenue by Region
- 7.1.1 Global Human Fibrinogen Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Human Fibrinogen Revenue by Region (2021-2026)
- 7.1.3 Global Human Fibrinogen Revenue by Region (2027-2032)
- 7.1.4 Global Human Fibrinogen Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Human Fibrinogen Revenue (2021-2032)
- 7.2.2 North America Human Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Human Fibrinogen Revenue (2021-2032)
- 7.3.2 Europe Human Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Human Fibrinogen Revenue (2021-2032)
- 7.4.2 Asia-Pacific Human Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Human Fibrinogen Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Human Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL Behring
- 8.1.1 CSL Behring Company Information
- 8.1.2 CSL Behring Business Overview
- 8.1.3 CSL Behring Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Behring Human Fibrinogen Product Portfolio
- 8.1.5 CSL Behring Recent Developments
- 8.2 LFB Group
- 8.2.1 LFB Group Company Information
- 8.2.2 LFB Group Business Overview
- 8.2.3 LFB Group Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 LFB Group Human Fibrinogen Product Portfolio
- 8.2.5 LFB Group Recent Developments
- 8.3 Shanghai RAAS Blood Products
- 8.3.1 Shanghai RAAS Blood Products Company Information
- 8.3.2 Shanghai RAAS Blood Products Business Overview
- 8.3.3 Shanghai RAAS Blood Products Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Shanghai RAAS Blood Products Human Fibrinogen Product Portfolio
- 8.3.5 Shanghai RAAS Blood Products Recent Developments
- 8.4 Jiangxi Boya Bio-Pharmaceutical
- 8.4.1 Jiangxi Boya Bio-Pharmaceutical Company Information
- 8.4.2 Jiangxi Boya Bio-Pharmaceutical Business Overview
- 8.4.3 Jiangxi Boya Bio-Pharmaceutical Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Jiangxi Boya Bio-Pharmaceutical Human Fibrinogen Product Portfolio
- 8.4.5 Jiangxi Boya Bio-Pharmaceutical Recent Developments
- 8.5 Hualan Biological Engineering
- 8.5.1 Hualan Biological Engineering Company Information
- 8.5.2 Hualan Biological Engineering Business Overview
- 8.5.3 Hualan Biological Engineering Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Hualan Biological Engineering Human Fibrinogen Product Portfolio
- 8.5.5 Hualan Biological Engineering Recent Developments
- 8.6 Harbin Pacific Biopharmaceutical
- 8.6.1 Harbin Pacific Biopharmaceutical Company Information
- 8.6.2 Harbin Pacific Biopharmaceutical Business Overview
- 8.6.3 Harbin Pacific Biopharmaceutical Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Harbin Pacific Biopharmaceutical Human Fibrinogen Product Portfolio
- 8.6.5 Harbin Pacific Biopharmaceutical Recent Developments
- 8.7 GREEN CROSS
- 8.7.1 GREEN CROSS Company Information
- 8.7.2 GREEN CROSS Business Overview
- 8.7.3 GREEN CROSS Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GREEN CROSS Human Fibrinogen Product Portfolio
- 8.7.5 GREEN CROSS Recent Developments
- 8.8 Shanghai XinXing Medical
- 8.8.1 Shanghai XinXing Medical Company Information
- 8.8.2 Shanghai XinXing Medical Business Overview
- 8.8.3 Shanghai XinXing Medical Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Shanghai XinXing Medical Human Fibrinogen Product Portfolio
- 8.8.5 Shanghai XinXing Medical Recent Developments
- 8.9 Octapharma
- 8.9.1 Octapharma Company Information
- 8.9.2 Octapharma Business Overview
- 8.9.3 Octapharma Human Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Octapharma Human Fibrinogen Product Portfolio
- 8.9.5 Octapharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Human Fibrinogen Value Chain Analysis
- 9.1.1 Human Fibrinogen Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Human Fibrinogen Production Mode & Process
- 9.2 Human Fibrinogen Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Human Fibrinogen Distributors
- 9.2.3 Human Fibrinogen Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst